# Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

Study · id `cardio:ct-nct01169779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01169779](<https://clinicaltrials.gov/study/NCT01169779>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01169779

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.

## Technical summary

Registry record NCT01169779. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2016-10-13.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 391 participants (enrolled count; ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Primary completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Completion: 2011-12 (actual) (ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Results first posted: 2016-10-13 (ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Countries: China; Hong Kong SAR China; Malaysia; Thailand (ClinicalTrials.gov record NCT01169779, source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01169779-2016-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
- Acronym: GetGoal-M-Asia
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Lixisenatide (AVE0010)
- Intervention (Drug): Placebo
- Intervention (Device): Pen auto-injector
- Intervention (Drug): Metformin
- Intervention (Drug): Sulfonylurea
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia) (`cardio:pubmed-24639432`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f3dc2b609ab9b6105c5ae82d6b057ad206caefe7e4679918f7f36f0ebb7e1ed2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
